Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Lipigon Pharmaceuticals

Less than 1K followers
Overview
Investor views
All
Webcasts
Press releases
3rd party
ShowingAll content types

Press release2026-09-01 08:37

Förändringar i bolagets ledning och nytt fokus på lungsjukdomar

Lipigon Pharmaceuticals
Regulatory press release2026-05-18 17:55

Kommuniké från årsstämma 2026 i Lipigon Pharmaceuticals

Lipigon Pharmaceuticals
Press release2026-05-13 11:28

Valberedningens förslag till styrelse i Lipigon till Årstämman 2026

Lipigon Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-05-04 15:20

Nasdaq beslutar om avnotering av Lipigon från First North Growth Market

Lipigon Pharmaceuticals
Regulatory press release2026-04-27 22:40

Lipigon publicerar årsredovisning för 2025

Lipigon Pharmaceuticals
Regulatory press release2026-04-20 15:55

Lipigons styrelse drar tillbaka förslag till årsstämman om avnotering till följd av att Nasdaq Stockholm inlett en separat avnoteringsprocess

Lipigon Pharmaceuticals
Regulatory press release2026-04-15 15:25

Kallelse till årsstämma i Lipigon Pharmaceuticals AB

Lipigon Pharmaceuticals
Regulatory press release2026-04-15 13:40

Styrelsen för Lipigon föreslår att årsstämman beslutar om avnotering från Nasdaq First North Growth Market

Lipigon Pharmaceuticals
Regulatory press release2026-03-26 08:00

Lipigon publicerar bokslutskommuniké 2025

Lipigon Pharmaceuticals
Press release2026-02-16 13:48

Lipigon Pharmaceuticals lämnar lägesuppdatering

Lipigon Pharmaceuticals
Regulatory press release2025-12-22 15:40

Lipigon Pharmaceuticals genomför en översyn av bolagets läkemedelsutvecklingsprojekt och vidtar åtgärder för kostnadsbesparingar

Lipigon Pharmaceuticals
Press release2025-12-04 08:45

Investor Studios: Lipigon Pharmaceuticals VD & CMO presenterar live 15.00

Lipigon Pharmaceuticals
Press release2025-12-03 19:52

Lipigon Pharmaceuticals bjuder in till webbsänd presentation av top line-resultat i den pågående kliniska fas II-studien

Lipigon Pharmaceuticals
Regulatory press release2025-12-03 18:55

Lipigon Pharmaceuticals presenterar top line-data från den kliniska fas II-studien av Lipisense i patienter med förhöjda blodfettsnivåer

Lipigon Pharmaceuticals
Regulatory press release2025-12-03 18:55

Lipigon Pharmaceuticals presents top-line data from the Phase II clinical trial of Lipisense in patients with elevated blood lipid levels

Lipigon Pharmaceuticals
Press release2025-11-25 16:15

Lipigon Pharmaceuticals valberedning utsedd inför Lipigons årsstämma 2026

Lipigon Pharmaceuticals
Press release2025-11-21 12:19

Redeye: Lipigon (Q3 Review) - Topline Before Year-End

Lipigon Pharmaceuticals
Regulatory press release2025-11-20 08:00

Lipigon publicerar delårsrapport för januari - september 2025

Lipigon Pharmaceuticals
Regulatory press release2025-10-21 14:59

Lipigon utser Redeye AB till ny Certified Adviser

Lipigon Pharmaceuticals
Press release2025-10-14 22:58

Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense

Lipigon Pharmaceuticals